Eunuchoidism Familial HypogonadotropicSymptoms, Doctors, Treatments, Advances & More
Eunuchoidism Familial Hypogonadotropic Overview
Learn About Eunuchoidism Familial Hypogonadotropic
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Unity Urology PC
. Dr. Carter is rated as a Distinguished provider by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Urinary Tract Infection in Children, Ureteroscopy, and Prostatectomy.
Advocate Medical Group Urology
James Griffin is a Urologist in Elgin, Illinois. Dr. Griffin is rated as an Advanced provider by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are Perirenal Abscess, Boils, Urinary Tract Infection in Children, Ureteroscopy, and Prostatectomy.
Texas Health Adult Care
Paul Anthony is a primary care provider, practicing in Internal Medicine and Geriatrics in Plano, Texas. Dr. Anthony is rated as an Advanced provider by MediFind in the treatment of Eunuchoidism Familial Hypogonadotropic. His top areas of expertise are High Cholesterol, Infant Hyperglycemia, Sitosterolemia, and Vitamin B12 Deficiency Anemia.
Summary: This is a 52-week open label single arm study to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.
Summary: To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testostero...


